ePT--the Electronic Newsletter of Pharmaceutical Technology, Aug 9, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Aug 9, 2012
News
Pfizer Settles with DOJ and SEC on Improper Conduct in Select Emerging Markets
By Patricia Van Arnum
An internal investigation and voluntary disclosure by Pfizer led to a settlement with the US Department of Justice and Securities and Exchange Commission.
Gilead Partners with Indian Manufacturers on HIV Medicines
By Amy Ritter
Gilead Sciences announced that it is entering into agreements with Indian generic drug manufacturers to enhance access in developing countries to its anti-HIV medicine, emtricitabine.
EMA Phases out Follow-Up Measures
By Susan Haigney
The European Medicines Agency (EMA) will soon be phasing out follow-up measures to marketing authorisations in place of a new system of classification that will be introduced in a stepwise manner.
Novartis in Cancer Collaboration with University of Pennsylvania
By Stephanie Sutton
Novartis has entered into a global collaboration with the University of Pennsylvania in the US to research, develop and commercialise targeted cancer therapies.
Week of August 6, 2012: Boehringer, Servier, Xoma Form Biomanufacturing Agreement; Teva Canada Completes Sale of Mirabel (Quebec) Facility to Halo Pharmaceutical; and More
Boehringer, Servier, Xoma Form Biomanufacturing Agreement; Teva Canada Completes Sale of Mirabel (Quebec) Facility to Halo Pharmaceutical; and More.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here